Pediatric high risk neuroblastoma with autologous stem cell transplant – 20 years of experience
| العنوان: | Pediatric high risk neuroblastoma with autologous stem cell transplant – 20 years of experience |
|---|---|
| المؤلفون: | Saadiya Khan, Ibrahim Ghemlas, Khulood AlSayyad, Abdullah Al-Jefri, Ibrahim Al-Fawaz, Ali Al-Ahmari, Amani Al-Kofide, Hassan El-Solh, Khawar Siddiqui, Hawazen Saleh Alsaedi, Amal Al-Seraihy, Mouhab Ayas, Awatif Alanazi, Afshan A. Ali |
| المصدر: | International Journal of Pediatrics & Adolescent Medicine International Journal of Pediatrics and Adolescent Medicine, Vol 8, Iss 4, Pp 253-257 (2021) |
| بيانات النشر: | King Faisal Specialist Hospital and Research Centre, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Melphalan, medicine.medical_specialty, 050402 sociology, medicine.medical_treatment, Pediatrics, RJ1-570, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, 0504 sociology, 030225 pediatrics, Internal medicine, medicine, Etoposide, Pediatric, Chemotherapy, High-risk neuroblastoma, business.industry, 05 social sciences, Induction chemotherapy, Carboplatin, Radiation therapy, Regimen, medicine.anatomical_structure, Autologous stem cell transplant, chemistry, Pediatrics, Perinatology and Child Health, Original Article, Bone marrow, business, medicine.drug |
| الوصف: | Background and Objective Neuroblastoma is the most common extracranial solid tumor found in pediatric patients. High-risk neuroblastoma (HR-NBL) can be characterized by metastasis, age, and other tumor characteristics that result in an adverse outlook for this patient cohort. The standard of care includes induction chemotherapy, surgery, followed by stem cell autologous transplant (ASCT), and later, antidisialoganglioside (anti-GD2) antibodies. In this study, we provide the survival and toxicity data of our HR-NBL patients treated with a single ASCT. Methods We retrospectively analyzed pediatric HR-NBL patients treated with single ASCT after a carboplatin, etoposide, and melphalan (CEM) regimen in our institution between January 1993 and December 2014. Results There were 99 evaluable patients with male predominance. The median age at diagnosis was 3 years. Most of our HR-NBL patients were stage 4 (88%). All patients received ASCT. Peripheral blood was the graft source in 58% of the patients. Time for hematological count recovery with bone marrow as a graft source was prolonged but not statistically significant when compared with PBSCs. Of all the patients, 58% received radiation therapy to residual disease. Overt secondary leukemia was not seen in any of these patients. Three-year overall survival (OS) was 68.5% ± 5.2% and the 3-year event-free survival (EFS) was (48.3% ± 5.2%). Conclusion Our HR-NBL patients tolerated high-dose chemotherapy well followed by single autologous stem cell transplant. Tandem transplant is a feasible option in our patient cohort. Apart from secondary solid tumors, there were no long-term complications seen. |
| اللغة: | English |
| تدمد: | 2352-6467 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64e4875847a9094c6a2c20643c319c30Test http://europepmc.org/articles/PMC8356102Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....64e4875847a9094c6a2c20643c319c30 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23526467 |
|---|